Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models

Abstract Unresectable hepatocellular carcinoma (uHCC) is one of the most lethal and prevalent cancers worldwide, and current systemic therapeutic options for uHCC are limited. Lenvatinib, a multiple receptor tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors (VEGFRs) an...

Fuld beskrivelse

Saved in:
Bibliografiske detaljer
Main Authors: Masahiro Matsuki, Taisuke Hoshi, Yuji Yamamoto, Megumi Ikemori‐Kawada, Yukinori Minoshima, Yasuhiro Funahashi, Junji Matsui
Format: Article
Sprog:engelsk
Udgivet: Wiley 2018-06-01
Serier:Cancer Medicine
Fag:
Online adgang:https://doi.org/10.1002/cam4.1517
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!